艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究

doi:10.3969/j.issn.1673-9701.2024.11.016

科研成果详情

题名	艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究
其他题名	Retrospective study on the treatment of patients with primary immune thrombocytopenia with atrepopa
作者	金珍琳; 金婷; 庄强
发表日期	2024-04-18
发表期刊	中国现代医生影响因子和分区
语种	中文
原始文献类型	学术期刊
关键词	艾曲泊帕原发免疫性血小板减少症免疫功能不良反应
其他关键词	Eltrombopag ; Thrombocytopenia ; Immune function ; Adverse reactions
摘要	目的探究艾曲泊帕治疗原发免疫性血小板减少症(primary immune thrombocytopenia,ITP)患者的回顾性研究。方法回顾性分析2018年10月至2022年2月于笔者医院接受治疗的90例ITP患者的病历资料,根据不同治疗方式,分为地塞米松组和艾曲泊帕组,地塞米松组采用地塞米松治疗,艾曲泊帕组在地塞米松组基础上联合艾曲泊帕治疗(均n=45)。比较免疫功能、治疗效果及不良反应。结果治疗后4周,白细胞介素[(interleukin)-2,IL-2]、干扰素-γ(interferon-gamma,INF-γ)水平比较,艾曲泊帕组及地塞米松组均较治疗前降低,且艾曲泊帕组低于地塞米松组,IL-4水平比较,艾曲泊帕组及地塞米松组较治疗前提高,且艾曲泊帕组高于地塞米松组(P<0.05)。治疗后4周,艾曲泊帕组及地塞米松组血小板(platelet,PLT)计数≥30×109/L比例分别为68.89%、40.00%,PLT≥50×109/L比例分别为55.55%、20.00%,艾曲泊帕组各比例均高于地塞米松组(P<0.05),治疗4周内,艾曲泊帕组及地塞米松组1/2时间PLT≥50×109/L比例分别为66.67%、33.33%,至少1次PLT≥50×109/L比例分别为93.33%、44.44%,治疗9个月至少1次PLT≥50×109/L比例分别为60.00%、26.67%,艾曲泊帕组高于地塞米松组(P<0.05)。艾曲泊帕组及地塞米松组不良反应率比较(P>0.05)。结论艾曲泊帕可明显降低ITP患者出血风险,改善免疫功能,提升治疗效果,同时治疗安全性较高。
其他摘要	Objective To investigate the retrospective study of the treatment of primary immune thrombocytopenia(ITP)with Aitracopol.Methods Medical records of 90 patients with ITP who received treatment in our hospital from October 2018 to February 2022 were retrospectively analyzed and grouped according to different treatment methods,with an average n=45.Dexamethasone group was treated with dexamethasone group,and itrepopopa group was treated with dexamethasone group and itrepopopa group combined with dexamethasone group,all n=45.The immune function,therapeutic effect and adverse reactions were compared.Results At 4 weeks after treatment,the levels of interleukin(IL)-2 and interferon(INF)-γ in the Altropopar group and dexamethasone group were lower than before treatment,and the levels of IL-4 in the Altropopar group and dexamethasone group were higher than before treatment.Aitripopal group was higher than dexamethasone group(P<0.05);At 4 weeks after treatment,the proportions of platelet(PLT)≥30×109/L were 68.89%and 40.00%in the Altropopar group and dexamethasone group,and the proportions of PLT≥50×109/L were 55.55%and 20.00%,respectively.The proportions in the Altropopar group were higher than those in the dexamethasone group(P<0.05).The proportions of PLT≥50×109/L in the half time and dexamethasone groups were 66.67%and 33.33%,respectively,and the proportions of PLT≥50×109/L for at least one time were 93.33%and 44.44%,respectively.The proportions of PLT≥50×109/L at least once after 9 months of treatment were 60.00%and 26.67%,respectively,and the attripopal group was higher than dexamethasone group(P<0.05).A comparison of the adverse reaction rate between aitopopal group and dexamethasone group(P0.05).Conclusion Aitracopal can significantly reduce the risk of bleeding in patients with ITP,improve immune function,improve therapeutic effect,and high safety.
资助项目	浙江省温州市基础性医疗卫生科技项目(Y2020548);
ISSN	1673-9701
卷号	62 期号:11 页码:69-72
DOI	10.3969/j.issn.1673-9701.2024.11.016
页数	4
收录类别	CNKI ; 维普 ; 万方
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/213006
专题	附属第一医院附属第一医院_血液内科
通讯作者	金珍琳
作者单位	温州医科大学附属第一医院血液内科
第一作者单位	附属第一医院; 血液内科
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	金珍琳,金婷,庄强. 艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究[J]. 中国现代医生,2024,62(11):69-72.
APA	金珍琳, 金婷, & 庄强. (2024). 艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究. 中国现代医生, 62(11), 69-72.
MLA	金珍琳,et al."艾曲泊帕治疗原发免疫性血小板减少症患者的回顾性研究".中国现代医生 62.11(2024):69-72.